Why Iovance Biotherapeutics Stock Hit 52-Week High

Iovance Biotherapeutics to Present at Upcoming Conferences

Iovance Biotherapeutics announced that senior leadership will present at the Wells Fargo Healthcare Conference (September 10) and H.C. Wainwright Global Investment Conference (September 15). The company reported record Q2 2026 revenue of approximately $99M, with U.S. Amtagvi revenue reaching ~$91M and 66% year-over-year growth. Gross margin improved to 56%, and the FDA granted Fast Track Designation for lifileucel in soft tissue sarcomas.

Advanced Endometrial Cancer Clinical Trial Pipeline Analysis: 25+ Key Companies Shaping the Future of Advanced Endometrial Cancer Therapeutics Space | DelveInsight

DelveInsight released a comprehensive analysis of the advanced endometrial cancer clinical trial pipeline, identifying 25+ active pharmaceutical companies developing 26+ pipeline drugs. The report highlights emerging therapies including immunotherapies, targeted agents, and antibody-drug conjugates (ADCs) from major players like Pfizer, Genmab, and Incyte Corporation. Recent developments include FDA Fast Track designation for Faeth Therapeutics' PIKTOR combination therapy and positive Phase III results for Merck's sacituzumab tirumotecan, indicating significant momentum in reshaping the advanced endometrial cancer treatment landscape.

Wells Fargo Maintains Overweight on Merck & Co, Raises Price Target to $170

Want $500 a Month in Passive Income? Start With This Brilliant Dividend ETF.

The Schwab U.S. Dividend Equity ETF (SCHD) is recommended as an effective vehicle for generating sustainable passive income through dividends. With a 3.2% yield and a history of increasing annual dividends since 2011, investors would need approximately $187,500 invested to generate $500 monthly in dividend income. The fund focuses on high-quality dividend-paying stocks and has delivered 13.4% annual returns since inception.

BioNTech vs. Moderna: Which Is the Better Cancer Vaccine Stock to Buy Now?

BioNTech and Moderna, both mRNA vaccine pioneers during the pandemic, are now pivoting to cancer vaccines as COVID revenue declines. Moderna is favored due to stronger recent clinical progress, including positive phase 3 results for its personalized cancer vaccine intismeran autogene and FDA approval for mFLUSIVA flu vaccine. While BioNTech has a deep pipeline including pumitamig, it has yet to deliver comparable phase 3 wins. Moderna's $61.2 billion market cap reflects investor confidence in its near-term commercialization prospects versus BioNTech's $26 billion valuation.

Does Moderna's mRNA Flu Shot Face a New Challenge From GSK?

Moderna secured FDA approval for mFlusiva, the first mRNA-based seasonal flu vaccine, establishing a foothold in the multibillion-dollar flu vaccine market. However, GSK announced plans to advance its own mRNA flu vaccine into phase III trials, which targets two viral proteins (HA and NA) and showed superior immune responses in phase II studies. While GSK's vaccine is still years away from market approval, it could pose a competitive challenge to Moderna's mFlusiva, which currently targets only HA like traditional flu vaccines.